Artiva Biotherapeutics, Inc. Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics, Inc.

ARTV

Rank in Stocks #16537
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm... Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
Share Price
$3.86
Last synced: 2026-11-17
Market Cap
$197.64M
Change (1 day)
-2.53%
Change (1 year)
23.32%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Trade Artiva Biotherapeutics, Inc. (ARTV)

Category

Healthcare
EPS for Artiva Biotherapeutics, Inc. (ARTV)
EPS as of September 2026 TTM: $-2.99
According to Artiva Biotherapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-2.99. At the end of 2025 the company had an EPS of $-3.43, an increase over its 2024 EPS of $-5.20.
EPS history for Artiva Biotherapeutics, Inc. from 2020 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $-2.99 -12.83%
2025 $-3.43 -34.04%
2024 $-5.20 336.97%
2023 $-1.19 -64.16%
2022 $-3.32 -18.63%
2021 $-4.08 300.00%
2020 $-1.02 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$-0.89 -70.23%
US
$15.66 -623.75%
US
$-7.07 136.45%
US
$-5.29 76.92%
AU
$12.73 -525.83%
BE

Questions about Artiva Biotherapeutics, Inc.'s earnings per share (EPS)

What is Artiva Biotherapeutics, Inc.'s earnings per share (EPS)?

Artiva Biotherapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-2.99, as of Sep 2026.

What was Artiva Biotherapeutics, Inc.'s earnings per share (EPS) in 2025?

In 2025, Artiva Biotherapeutics, Inc.'s earnings per share (EPS) was $-3.43, compared with $-5.20 in 2024.

How has Artiva Biotherapeutics, Inc.'s earnings per share (EPS) changed since 2020?

From 2020 to 2025, Artiva Biotherapeutics, Inc.'s earnings per share (EPS) was highest in 2020 ($-1.02) and lowest in 2024 ($-5.20).

How does Artiva Biotherapeutics, Inc.'s earnings per share (EPS) compare with similar companies?

Artiva Biotherapeutics, Inc.'s earnings per share (EPS) ($-2.99) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.